Evaluation of the efficacy of a hepatoprotector for the treatment of toxic (drug-induced) liver injury

Introduction. Toxic liver injury is widespread among patients, especially those with comorbidities and polypharmacy. The non-specific clinical manifestations and significant variability in liver and systemic changes complicate timely diagnosis and initiation of treatment.

Aim. To evaluate the effectiveness of therapy for toxic (drug-induced) liver injury using a hepatoprotective agent containing inosine, meglumine, methionine, nicotinamide and succinic acid.

Materials and methods. A total of 178 patients (152 men, 26 women) with confirmed drug-induced liver injury were examined. The main group (n = 104) received hepatoprotective agent containing inosine, meglumine, methionine, nicotinamide and succinic acid intravenously (400–800 ml, up to 14 days) in addition to standard therapy. The control group received conventional detoxification and symptomatic treatment. Clinical and laboratory evaluation was performed, including assessment of liver function biochemical markers.

Results. By day 21, the main group showed a statistically significant improvement: ALT decreased from 531 ± 112 to 46 ± 25 U/L, AST from 587 ± 126 to 41 ± 35 U/L, ALP from 378 ± 76 to 86 ± 44 U/L, GGT from 418 ± 92 to 58 ± 24 U/L; albumin increased from 29 ± 4 to 41 ± 3 g/L, and the prothrombin index from 54 ± 12 to 94 ± 6% (p < 0.001). Improvements in the control group were less pronounced.

Conclusion. Hepatoprotective agent containing inosine, meglumine, methionine, nicotinamide and succinic acid demonstrated efficacy by reducing several adverse clinical manifestations of toxic (drug-induced) liver injury, including resolution of cytolysis and cholestasis syndromes, restoration of protein-synthetic liver function, and improvement of hematological parameters.

1. Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950–966. https://doi.org/10.1038/ajg.2014.131.

2. Molostvova AF, Khabirova GI, Kharisova YI, Salimova LM. Drug-induced liver injury – modern view on the correct problem. Bulletin of Contemporary Clinical Medicine. 2022;15(5):107–115. (In Russ.) https://doi.org/10.20969/VSKM.2022.15(5).107-115.

3. Pavlov A, Karakozov A, Molodova A, Denisova O, Kazakov S. Drug-drug liver injury in patients NAFLD with COVID-19. Clinica Chimica Acta. 2024;558(1):119231. https://doi.org/10.1016/j.cca.2024.119231.

4. Yu YC, Mao YM, Chen CW, Chen JJ, Chen J, Cong WM et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017;11(3):221–241. https://doi.org/10.1007/s12072-017-9793-2.

5. Bjornsson ES. Drug-induced liver injury: an overview over the most critical compounds. Arch Toxicol. 2015;89(3):327–334. https://doi.org/10.1007/s00204-015-1456-2.

6. Padappayil RP, Borger J. Ammonia Toxicity. In: StatPearls. Treasure Island (FL): Stat Pearls Publishing; 2023. Available at: https://pubmed.ncbi.nlm.nih.gov/31536283/.

7. Ivashkin VT, Raikhelson KL, Palgova LK, Maevskaya MV, Gerasimova OA, Kondrashina EA et al. Drug-induced liver injury in cancer patients. Oncogematologiya. 2020;15(3):80–94. (In Russ.) https://doi.org/10.17650/1818-8346-2020-15-3-80-94.

8. Guo C, Liu W, Liu Z, Cai J, Yu X, Wang H et al. Scavenger receptor a is a major homeostatic regulator that restrains drug-induced liver injury. Hepatology. 2023;78(1):45–57. https://doi.org/10.1097/HEP.0000000000000044.

9. Ma ZT, Shi Z, Xiao XH, Wang JB. New Insights into Herb-Induced Liver Injury. Antioxid Redox Signal. 2023;38(16-18):1138–1149. https://doi.org/10.1089/ars.2022.0134.

10. Ghabril M, Fontana R, Rockey D, Jiezhun G, Chalasani N. Drug-induced liver injury caused by intravenously administered medications: the DrugInduced Liver Injury Network experience. J Clin Gastroenterol. 2013;47(6):553–558. https://doi.org/10.1097/MCG.0b013e318276bf00.

11. Буеверов АО (ред.). Основы гепатологии. М.: Издательский дом «АБВ-пресс»; 2022. 408 с.

12. Humphries C, Dear JW. Novel biomarkers for drug-induced liver injury. Clin Toxicol. 2023;61(8):567–572. https://doi.org/10.1080/15563650.2023.2259089.

13. Hoofnagle JH, Serrano J, Knoben JE, Navarro VG. LiverTox: a website on drug-induced liver injury. Hepatology. 2013;57(3):873–874. https://doi.org/10.1002/hep.26175.

14. Molodova AI, Pavlov AI, Kazakov SP, Karakozov AG. Investigation of hematological, biochemical and coagulological markers, their diagnostic effectiveness in toxic hepatitis in patients with COVID-19. Medical Alphabet. 2024;(20):18–24. (In Russ.) https://doi.org/10.33667/2078-5631-2024-20-18-24.

15. Maev IV, Polunina TE. Drug-induced liver injury: diagnosis of exclusion. Terapevticheskii Arkhiv. 2023;95(8):611–620. (In Russ.) https://doi.org/10.26442/00403660.2023.08.202329.

16. Mao Y, Ma S, Liu C, Liu X, Su M, Li D et al. Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update. Hepatol Int. 2024;18(2):384–419. https://doi.org/10.1007/s12072-023-10633-7.

17. Лазебник ЛБ, Голованова ЕВ, Алексеенко СА, Арямкина ОЛ, Бакулин ИГ, Бакулина НВ и др. Лекарственные поражения печени (ЛПП) у взрослых: клинические рекомендации. М.; 2022. Режим доступа: http://disuria.ru/_ld/12/1223_kr22K71MZ.pdf.

18. Mazina NK, Mazin PV. Metaanalytic Approach to Evaluate Clinical Effectiveness of Infusion Succinnate-Containing Remaxol in Liver Pathologies of Diverse Genesis. Antibiotiki i Khimioterapiya. 2015;60(11-12):43–49. (In Russ.) Available at: https://www.antibiotics-chemotherapy.ru/jour/article/view/631/631.

19. Dukić M, Radonjić T, Jovanović I, Zdravković M, Todorović Z, Kraišnik N et al. Alcohol, Inflammation, and Microbiota in Alcoholic Liver Disease. Int J Mol Sci. 2023;24(4):3735. https://doi.org/10.3390/ijms24043735.

20. Maev IV, Shaburov RI, Pavlov AI, Molodova AI, Karakozov AG, Kazakov SP et al. Treatment of toxic hepatitis in COVID-19 patients. Terapevticheskii Arkhiv. 2022;94(12):1413–1420. (In Russ.) https://doi.org/10.26442/00403660.2022.12.202021.